Navigation Links
Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook
Date:7/29/2009

d compensation arrangements 1.0 0.6 0.9 0.4 --- --- --- --- Diluted weighted average common shares outstanding 118.8 117.7 118.5 117.5 ===== ===== ===== ===== (1) Includes accelerated depreciation charges.

The following table presents a reconciliation of reported net income for the three and six months ended June 30, 2009 and 2008 to adjusted EBITDA:

                                                                   Table 5
                            Watson Pharmaceuticals, Inc.
                        Adjusted EBITDA Reconciliation Table
                              (Unaudited; in millions)

                                              Three Months    Six Months
                                                 Ended           Ended
                                                June 30,        June 30,
                                              2009    2008    2009    2008
                                              ----    ----    ----    ----
    GAAP net income                          $53.0   $60.3  $102.1  $110.9
    Plus:
            Interest expense                   4.6     6.9     9.3    13.7
            Interest income                   (1.3)   (1.7)   (3.3)   (4.0)
            Provision for income taxes        37.6    35.5    68.5    66.7
            Depreciation (includes
             accelerated depreciation)        24.1    22.5    47.3    44.2
            Amortization                      22.1    20.2    43.9    40.4
                                              ----    ----    ----    ----
    EBITDA                                   140.1   143.7   267.8   271.9
                                             -----   -----   -----   -----
    Adjusted for:

'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine news :

1. Watson Announces License Agreement With GeneraMedix for Generic Version of Ferrlecit(R)
2. Watson CFO Mark W. Durand to Take Leave of Absence
3. Watson Confirms Filing of Abbreviated New Drug Application for Generic Sanctura XR(R)
4. Watson Pharmaceuticals Receives a Complete Response Letter for Its 24-Week Formulation of TRELSTAR(R) (triptorelin pamoate) NDA from US FDA
5. Watson to Host Second Quarter 2009 Earnings Conference Call and Webcast
6. Watson Pharmaceuticals Resumes Shipment of INFeD(R) (Iron Dextran Injection, USP)
7. Watson Pharmaceuticals Receives FDA Approval for Fruit and Cinnamon Flavored Coated Nicotine Gums
8. Watson Pharmaceuticals Receives FDA Approval For Generic PLAN B(R)
9. Watson to Acquire Arrow Group
10. Watson Files FDA Application for Generic Mucinex(R) D
11. Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... AR (PRWEB) July 30, 2014 Throughout ... their patients with free oral cancer screenings. Using a ... will work to detect the disease in its early ... lips, tongue, cheek, mouth, sinuses, throat and other areas ... Cancer Institute’s Surveillance, Epidemiology, and Ends Results (SEER) program, ...
(Date:7/30/2014)... sub-Saharan Africa is being revitalized and expanded through ... broadening curricula, upgrading Internet access and providing cutting-edge ... the first substantial publication by participants of the ... than 225 authors detailed progress being made at ... supplement being published today by the journal ...
(Date:7/30/2014)... Alan Mozes HealthDay Reporter ... who want to help their preschooler shed excess pounds may ... Youngsters whose parents joined them in a supervised behavioral ... enrolled in a traditional child-only program (an average difference of ... benefited, losing almost 15 pounds over two years, according to ...
(Date:7/30/2014)... York (PRWEB) July 30, 2014 The ... brain bleeding has filed a Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ... blood thinner, Bernstein Liebhard LLP reports. According to the ... the District of Vermont on July 25th, the decedent ... he suffered an irreversible brain bleed that ultimately led ...
(Date:7/30/2014)... phrase "we caught it early" is possibly the best ... a cancer diagnosis. Combating cancer in its earliest stages, ... of the body, gives patients the best chances of ... and other forms of cancer are touted for saving ... cancer screenings as a precautionary measure, especially for high-risk ...
Breaking Medicine News(10 mins):Health News:Restore Dental Offers Complimentary Oral Cancer Screenings in August 2Health News:Journal supplement details progress in African medical education 2Health News:Journal supplement details progress in African medical education 3Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 2Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 3Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 4Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 3
... still too early to say that phthalates actually ... (HealthDay News) -- Common chemicals found in plastic toys ... breasts in boys, preliminary research suggests. , The ... adds fuel to the debate over these chemicals, called ...
... up within a week of getting news, researchers say ... can put newly diagnosed prostate cancer patients at increased ... has found. , Researchers analyzed data on 168,584 Swedish ... Of those men, 10,126 (6 percent) experienced a cardiovascular ...
... , LEXINGTON, Ky., Dec. ... confirmed today that VHGI Gold (a wholly owned operating subsidiary ... VHGI advisory board to assist with bringing the Treasure Gulch ... possible. Additionally, the company is informing interested shareholders and related ...
... , , NEW YORK, Dec. ... research report is available in its catalogue: , ... - Market Forecasts to 2015, Competitive Benchmarking, Product ... http://www.reportlinker.com/p0168100/The-Future-of-Autoimmune-Diseases-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html , Summary , The ...
... Ill. and CHENNAI, India, Dec. 15 Hospira, Inc. ... generic injectable pharmaceuticals, and Orchid Chemicals & Pharmaceuticals Ltd. ... and among the top-five generic beta-lactam antibiotics manufacturers globally, ... generic injectable finished-dosage form pharmaceuticals business for approximately $400 ...
... are often treated with hormones, but when the tumours ... vessels, reveals a thesis from the Sahlgrenska Academy, at ... way for new treatments for hormone-resistant prostate cancer. ... prostate cancer has spread, most patients are given hormone ...
Cached Medicine News:Health News:Breast Growth in Boys Might Be Linked to Plastics Chemical 2Health News:Breast Growth in Boys Might Be Linked to Plastics Chemical 3Health News:VHGI: VHGI Gold Taps Key Mining Professionals to Assist With Development Plan for $50,000,000 Potential Reserves at Treasure Gulch Gold Mine; Investor Town Hall Meeting to be Scheduled 2Health News:VHGI: VHGI Gold Taps Key Mining Professionals to Assist With Development Plan for $50,000,000 Potential Reserves at Treasure Gulch Gold Mine; Investor Town Hall Meeting to be Scheduled 3Health News:VHGI: VHGI Gold Taps Key Mining Professionals to Assist With Development Plan for $50,000,000 Potential Reserves at Treasure Gulch Gold Mine; Investor Town Hall Meeting to be Scheduled 4Health News:VHGI: VHGI Gold Taps Key Mining Professionals to Assist With Development Plan for $50,000,000 Potential Reserves at Treasure Gulch Gold Mine; Investor Town Hall Meeting to be Scheduled 5Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 4Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 5Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 6Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 7Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 8Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 9Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 10Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 11Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 12Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 13Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 14Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 15Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 16Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 17Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 18Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 19Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 20Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 21Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 22Health News:Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 23Health News:Hospira to Acquire Orchid's Generic Injectable Pharmaceuticals Business 2Health News:Hospira to Acquire Orchid's Generic Injectable Pharmaceuticals Business 3Health News:Hospira to Acquire Orchid's Generic Injectable Pharmaceuticals Business 4Health News:Hospira to Acquire Orchid's Generic Injectable Pharmaceuticals Business 5Health News:Hospira to Acquire Orchid's Generic Injectable Pharmaceuticals Business 6Health News:More blood vessels in hormone-resistant prostate tumors 2
(Date:7/30/2014)... TARRYTOWN, N.Y. and PARIS ... REGN ) and Sanofi (EURONEXT: SAN and ... new Phase 3 ODYSSEY trials of alirocumab in people ... greater percent reduction from baseline in low-density lipoprotein cholesterol ... comparator.  Alirocumab is an investigational monoclonal antibody targeting PCSK9 ...
(Date:7/30/2014)... , July 30, 2014 ACCESS PHARMACEUTICALS, ... oncology supportive care, announced that its novel product for ... an article on OncLive.com titled, "Study Finds Mouth Rinse ... Dr. Steve Sonis , a leading expert in ... in the oncology community for evidence-based strategies for the ...
(Date:7/30/2014)... SAN ANTONIO , July 30, 2014 /PRNewswire/ ... technology company focused on innovating lifesaving devices and ... closed $4.5 million in Series A financing, which ... .  Proceeds from the deal will allow Bluegrass ... Inside-Out Access Catheter System, enhance manufacturing capabilities, and ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2
... May 26 Hill-Rom Holdings, Inc., (NYSE: HRC ) invites ... president and chief financial officer, Hill-Rom.  He will be speaking at the Jefferies ... June 9, 2010 , at 1:30 p.m. EDT .     , ... You are invited to listen to the ...
... Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today announced ... its strategic advisor as it pursues various avenues aimed at ... ANA598, in development for the treatment of hepatitis C.  Anadys ... conclusion of 12 weeks of dosing ANA598 in combination with ...
Cached Medicine Technology:Hill-Rom to Present at the Jefferies Global Life Sciences Conference 2Anadys Retains Lazard as Strategic Advisor 2Anadys Retains Lazard as Strategic Advisor 3Anadys Retains Lazard as Strategic Advisor 4Anadys Retains Lazard as Strategic Advisor 5
The Onar®Lp -QP test system is an in vitro test for the quantitative diagnosis of legionella in clinical samples....
The GoodKnight® 425 Bi-Level® device is suitable for travel and includes features such as automatic altitude compensation, optional cigarette lighter adapter and portable battery pack...
... Bi-Flex bi-level system, while in BiPAP mode, ... takes to change from EPAP to IPAP. ... automatically triggers the device to cycle between ... patients breathing rhythm. Auto-Trak also compensates for ...
Functional trainer...
Medicine Products: